A Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Patients With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Patients With Metastatic Colorectal Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Migoprotafib (Primary) ; Osimertinib (Primary)
Indications Adenocarcinoma; Colon cancer; Lung cancer; Non-small cell lung cancer; Rectal cancer
Focus Adverse reactions
Sponsors Genentech

Most Recent Events

27 Aug 2024 Status changed from recruiting to active, no longer recruiting.
05 Jan 2024 Planned initiation date changed from 31 Oct 2023 to 15 Jan 2024.
09 Nov 2023 Planned End Date changed from 30 Dec 2026 to 31 Dec 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight